Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies

Novel Agents on the Horizon for Cancer Therapy

(2009) W. W. Ma et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche

(2009) Janine T. Erler et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

(2009) L. Xu et al.   CANCER RESEARCH

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) W. Wang et al.   CLINICAL CANCER RESEARCH

Anti-vascular endothelial growth factor therapy for malignant glioma

(2009) Elizabeth R. Gerstner et al.   Current Neurology and Neuroscience Reports

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

(2009) Annamaria Rapisarda et al.   DRUG RESISTANCE UPDATES

Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer

(2009) Giuseppe Di Lorenzo et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

(2009) F. Shojaei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies

(2008) Richard C. A. Sainson et al.   ANGIOGENESIS

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

Immune surveillance: a balance between protumor and antitumor immunity

(2008) Suzanne Ostrand-Rosenberg   CURRENT OPINION IN GENETICS & DEVELOPMENT

Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis

(2008) Manfred Johannsen et al.   EUROPEAN UROLOGY

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells

(2008) Ilaria Marigo et al.   IMMUNOLOGICAL REVIEWS

Chemotherapeutic drugs and human tumor cells cytokine network

(2008) Vera Levina et al.   INTERNATIONAL JOURNAL OF CANCER

Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy

(2008) Marcus Czabanka et al.   INTERNATIONAL JOURNAL OF CANCER

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

(2008) J. Ma et al.   MOLECULAR CANCER THERAPEUTICS

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

(2008) H. Burris et al.   ONCOLOGIST

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

(2008) F. Shojaei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA